Skip to main navigation

Manage Cookie Consent

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively.

Functional Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage options Manage services Manage vendors Read more about these purposes

View preferences

Privacy and Cookie Notice {title} {title}

Home
About
Pipeline
Investors
Contact

News & Events

Company Overview
News & Events
- News Releases
- Events & Presentations
Stock Information
Financial Information
Corporate Governance
IR Resources
- Email Alerts
- Contact IR

News Category

Year

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Jul 09, 2026

PDF Version

Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome

Jun 30, 2026

PDF Version

Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome

Jun 23, 2026

PDF Version

Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003

Jun 18, 2026

PDF Version

Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program

Jun 16, 2026

PDF Version

Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

Jun 04, 2026

PDF Version

Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome

Jun 02, 2026

PDF Version

Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 07, 2026

PDF Version

Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026

Apr 30, 2026

PDF Version

Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Apr 28, 2026

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 17

Past Events

There are no past events available at this time.

Presentations

Corporate Overview 2.4 MB

Subscribe

Sign up for alerts to stay up to date on Quoin Pharmaceuticals.

News:

Jul 09, 2026

Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome

Jun 30, 2026

Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome

2026 © Quoin Pharmaceuticals, Inc. Privacy Policy